# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Cyclo Therapeutics (NASDAQ:CYTH) with a Buy rat...
Ascendiant Capital analyst Lucas Ward initiates coverage on Cyclo Therapeutics (NASDAQ:CYTH) with a Buy rating and announces...
https://register.epo.org/application?number=EP19805439
Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology ...